Trastuzumab-Botidotin: Advancing HER2-targeted therapy into a new era of dual-epitope synergistic effects
As precision oncology continues to evolve, HER2 (human epidermal growth factor receptor 2) has become one of the most established and clinically valuable therapeutic targets across a wide range of solid tumors. With growing insight into tumor heterogeneity and resistance mechanisms, the limitations of single-target, single-mechanism therapies are increasingly apparent. Improving efficacy while...
0 Σχόλια 0 Μοιράστηκε 549 Views 0 Προεπισκόπηση